According to an analysis led by US-based Prime Therapeutics and published in the Journal of Managed Care & Specialty Pharmacy in August, on average only one-third of people continue taking GLP-1...

cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care  Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...

Nov. 29, 2024 - ustekinumab-kfce (Yesintek) The FDA has approved Biocon’s Yesintek as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is indicated for all...

Real-World 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members without Diabetes This study earned a silver award from AMCP. It...

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

2M HighTouchRx® has contributed to more than $200 million in savings across commercial and Medicare plans since 2022. Prime serves approximately 6 million Floridians. IntegratedRx® connects...

The Spring 2026 Prime Therapeutics Report delivers a forward-looking view of specialty and rare disease management—highlighting breakthrough approvals, expanding pipelines and the payer strategies...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in Las Vegas.